Anti-inflammatory effect of patchouli alcohol isolated from Pogostemonis Herba in LPS-stimulated RAW264.7 macrophages

Experimental and Therapeutic Medicine

Volumn 2, Issue 3, 2011, Pages 545-550

  Xian, Yan Fang ^a   Li, Yu Cui ^b   Ip, Siu Po ^a   Lin, Zhi Xiu ^a   Lai, Xiao Ping ^b   Su, Zi Ren ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Anti inflammatory effect; Lipopolysaccharide; Patchouli alcohol; Ppogostemonis Hherba; RAraW264.7 macrophages

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; HERBACEOUS AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; NITRIC OXIDE; PATCHOULI ALCOHOL; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CHINESE MEDICINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DOWN REGULATION; DRUG ISOLATION; DRUG STRUCTURE; MOUSE; NONHUMAN; POGOSTEMONIS HERBA; PROTEIN SYNTHESIS;

EID: 79953268050     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.233     Document Type: Article

References (49)

1. Chinese Pharmacopoeia Committee: Pharmacopoeia of China. Chinese Medical Science and Technology Press, Beijing, 2010.
2. Zhang D, Xiao LY, Cheng YW, Li HL, Feng ZM, Lin PY, Wu WY and Huang KR: Pharmacological action of Baoji Pill. Tradit Chin Drug Res Clin Pharmacol 9: 212-214, 1998.
3. Xian YF, Suo J, Huang XD, Hou SZ, Chen JN, Ye MR and Su ZR: A pharmacological study on anti-inflammatory effects of refined Huodan recipe. Chin J Exp Tradit Med Formul 13: 54-56, 2007.
4. Yang Y, Kinoshita K, Koyama K, Takahashi K, Tai T, Nunoura Y and Watanabe K: Anti-emetic principles of Pogostemon cablin (Blanco) Benth. Phytomedicine 6: 89-93, 1999.
5. Zhao SC, Jia Q and Liao FL: The anti-inflammatory and analgesic pharmacological study of Patchouli extract. Chin Tradit Pat Med 29: 285-287, 2007.
6. Suo J, Xian YF, Huang XD, Hou SZ, Chen JN, Ye MR and Su ZR: A pharmacological study on the anti-allergy effects of refined Houdan recipe. Chin J Exp Tradit Med Formul 13: 47-49, 2007.
7. Qi SS, Hu LP, Chen WN, Sun HB and Ma XD: Immunological regulation effects of essential oil in leaves of Cablin Patchouli herbal on mice. Chin Arch Tradit Chin Med 27: 774-776, 2009.
8. Liu XR, Fan R, Zhang YY and Zhu MJ: Study on antimicrobial activities of extracts from Pogestemon cablin (Blanco) Benth. Food Sci Technol 24: 220-227, 2009.
9. Yang D, Chaumont JP and Millet J: Antifungal activity of the essential oils from Agastache rugosa and Pogostemon cablin against dermatophytes and opportunistic fungi. Zhongguo Yao Xue Za Zhi 35: 9-11, 2000.
10. Park EJ, Park HR, Lee JS and Kim J: Licochalcone A: an inducer of cell differentiation and cytotoxic agent from Pogostemon cablin. Planta Med 64: 464-466, 1998.
11. Miyazawa M, Okuno Y, Nakamura S and Kosaka H: Suppression of the furylfuramide-induced SOS response by monoterpenoids with a p-menthane skeleton using the Salmonella typhimurium TA1535/pSK1002 Umu test. J Agric Food Chem 48: 642-647, 2000.
12. Zhao ZZ, Lu J, Leung K, Chan CL and Jiang ZH: Determination of patchoulic alcohol in herba Pogostemonis by GC-MS-MS. Chem Pharm Bull 53: 856-860, 2005.
13. Huang XW, Bai L, Xu FH and Wu YJ: Inhibitory activities of patchouli alcohol on neurotoxicity of β-amyloid peptide. Jie Fang Jun Yi Xue Za Zhi 24: 338-340, 2008.
14. Huang XW, Liu RT and Lü QJ: Patchouli alcohol on memory impairment induced by scopolamine learning and memory function in mice. Zhong Yao Cai 40: 1431-1433, 2009.
15. Hu XD, Yang Y, Zhong XG, Zhang XH, Zhang YN, Zheng ZP, Zhou Y, Tang W, Wang YF, Hu LH and Zuo JP Antiinflammatory effects of Z23 on LPS-induced inflammatory responses in RAW264.7 macrophages. J Ethnopharmacol 120: 447-451, 2008.
16. Tao JY, Zheng GH, Zhao L, Wu JG, Zhang XY, Zhang SL, Huang ZJ, Xiong FL and Li CM: Anti-inflammatory effects of ethyl acetate fraction from Melilotus suaveolens Ledeb on LPS-stimulated RAW264.7 cells. J Ethnopharmacol 123: 97-105, 2009.
17. Liew FY: The role of innate cytokines in inflammatory response. Immunol Lett 85: 131-134, 2003.
18. Bertolini A, Ottani A and Sandrini M: Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 9: 1033-1043, 2002.
19. Isomaki P and Punnone J: Pro and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 29: 499-507, 1997.
20. Korhonen R, Lathi A, Kankaanranta H and Moilanen E: Nitric oxide production and signaling in inflammation. Curr Drug Targets Inflamm Allergy 4: 471-479, 2005.
21. Libby P, Aikawa M and Schönbeck U: Cholesterol and atherosclerosis. Biochim Biophys Acta 1529: 299-309, 2000.
22. Shin EM, Zhou HY, Guo LY, Kim JA, Lee SH, Merfort I, Kang SS, Kim HS, Kim S and Kim YS: Anti-inflammatory effects of glycyrol isolated from Glycyrrhiza uralensis in LPS-stimulated RAW264.7 macrophages. Int Immunopharmacol 8: 1524-1532, 2008.
23. Jeong GS, Lee DS and Kim YC: Cudratricus xanthone A from Cudrania tricuspidata suppresses pro-inflammatory mediators through expression of anti-inflammatory heme oxygenase-1 in RAW264.7 macrophages. Int Immunopharmacol 9: 241-246, 2009
24. Guan L, Quan LH, Xu LZ and Cong PZ: Chemical constituents of Pogostemon cablin (Blanco) Benth. Zhongguo Zhong Yao Za Zhi 19: 355-356, 1994.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 25: 402-408, 2001.
26. Zhang XJ, Li Y, Tai GX, Xu GY, Zhang FY, Yang Y, Lao FX and Liu ZH: Effects of activin A on the activities of mouse peritoneal macrophages. Cell Mol Immunol 2: 63-67, 2005.
27. Gayathri B, Manjula N, Vinaykumar KS, Lakshmi BS and Balakrishnan A: Pure compound from Boswellia serrata extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFα, IL-1β, NO and MAP kinases. Int Immunopharmacol 7: 473-482, 2007.
28. Palmer RM, Rees DD, Ashton DS and Moncada S: L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 153: 1251-1256, 1988.
29. Schmidt HH and Walter U: NO at work. Cell 78: 919-925, 1994.
30. MacMicking J, Xie QW and Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350, 1997.
31. Petros A, Bennett D and Vallance P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338: 1557-1558, 1991.
32. McCartney-Francis N, Allen JB, Mizel DE, Albina JE, Xie QW, Nathan CF and Wahl SM: Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 178: 749-754, 1993.
33. Kleemann R, Rothe H, Kolb-Bachofen V, Xie QW, Nathan C, Martin S and Kolb H: Transcription and translation of inducible nitric oxide synthase in the pancreas of prediabetic BB rats. FEBS Lett 328: 9-12, 1993.
34. Hobbs AJ, Higgs A and Moncada S: Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev pharmacol Toxicol 39: 191-220, 1999.
35. Pacher P, Joseph S, Beckman JS and Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424, 2007.
36. Lin QY, Jin LJ, Cao ZH and Xu YP: Inhibition of inducible nitric oxide synthase by Acanthopanax senticosus extract in RAW264.7 macrophages. J Ethnopharmacol 118: 231-236, 2008.
37. Claria J: Cyclooxygenase-2 biology. Curr Pharma Des 9: 2177-2190, 2003.
38. Rocca B and FitzGerald GA: Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol 2: 603-630, 2002.
39. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L and Isakson P: Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 91: 12013-12017, 1994.
40. Bondeson J: The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines. Gen Pharmacol 29: 127-150, 1997.
41. Andreakos E, Foxwell B and Feldmann M: Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 202: 250-265, 2004.
42. Dayer JM: The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract Res Clin Rheumatol 18: 31-45, 2004.
43. Shohami E, Ginis I and Hallenbeck JM: Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 10: 119-130, 1999.
44. Yoon HJ, Moon ME, Park HS, Im SY and Kim YH: Chitosan oligosaccharide (COS) inhibits LPS-induced inflammatory effects in RAW 264.7 macrophage cells. Biochem Biophys Res Commun 358: 954-959, 2007.
45. Straub RH, Linde DN, Mannel J, Scholmerich W and Falk A: A bacteria-induced switch of sympathetic effect or mechanisms augments local inhibition of TNF-α and IL-6 secretion in the spleen. FASEB J 14: 1380-1388, 2000.
46. Hibi M, Nakajima K and Hirano T: IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med 74: 1-12, 1996.
47. Hirano T, Matsuda T and Nakajima K: Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells 12: 262-277, 1994.
48. Van Snick J: Interleukin-6: an overview. Annu Rev Immunol 8: 253-278, 1990.
49. Taga T and Kishimoto T: Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819, 1997.